[go: up one dir, main page]

MX2011012836A - Adyuvantes sinteticos de glucopiranosil-lipido. - Google Patents

Adyuvantes sinteticos de glucopiranosil-lipido.

Info

Publication number
MX2011012836A
MX2011012836A MX2011012836A MX2011012836A MX2011012836A MX 2011012836 A MX2011012836 A MX 2011012836A MX 2011012836 A MX2011012836 A MX 2011012836A MX 2011012836 A MX2011012836 A MX 2011012836A MX 2011012836 A MX2011012836 A MX 2011012836A
Authority
MX
Mexico
Prior art keywords
glucopyranosyl lipid
lipid adjuvants
synthetic glucopyranosyl
compounds
synthetic
Prior art date
Application number
MX2011012836A
Other languages
English (en)
Inventor
Steven G Reed
Darrick Carter
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of MX2011012836A publication Critical patent/MX2011012836A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04Phosphates; Phosphites; Polyphosphates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/12Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan compuestos, particularmente compuestos de adyuvantes de glucopiranosil-lípido (GLA), que tienen la siguiente estructura (I): (I) o una sal farmacéuticamente aceptable de los mismos, en donde L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, son como se define en este documento. También se proporcionan composiciones farmacéuticas, composiciones de vacunas y métodos relacionados para inducir o mejorar las respuestas inmunológicas.
MX2011012836A 2009-06-05 2010-06-04 Adyuvantes sinteticos de glucopiranosil-lipido. MX2011012836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18470309P 2009-06-05 2009-06-05
PCT/US2010/037466 WO2010141861A1 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipid adjuvants

Publications (1)

Publication Number Publication Date
MX2011012836A true MX2011012836A (es) 2012-04-20

Family

ID=43298190

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014009221A MX360448B (es) 2009-06-05 2010-06-04 Adyuvantes sinteticos de glucopiranosil-lipido.
MX2018013361A MX393384B (es) 2009-06-05 2010-06-04 Adyuvantes sinteticos de glucopiranosil-lipido.
MX2011012836A MX2011012836A (es) 2009-06-05 2010-06-04 Adyuvantes sinteticos de glucopiranosil-lipido.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014009221A MX360448B (es) 2009-06-05 2010-06-04 Adyuvantes sinteticos de glucopiranosil-lipido.
MX2018013361A MX393384B (es) 2009-06-05 2010-06-04 Adyuvantes sinteticos de glucopiranosil-lipido.

Country Status (22)

Country Link
US (4) US8722064B2 (es)
EP (2) EP2437753B1 (es)
JP (3) JP5830015B2 (es)
CN (2) CN105131051B (es)
AU (1) AU2010256461B2 (es)
BR (1) BRPI1011072B1 (es)
CA (1) CA2764374C (es)
CY (1) CY1118347T1 (es)
DK (1) DK2437753T3 (es)
ES (1) ES2606563T3 (es)
HR (1) HRP20161585T1 (es)
HU (1) HUE031051T2 (es)
IL (2) IL216669A (es)
LT (1) LT2437753T (es)
MX (3) MX360448B (es)
PL (1) PL2437753T3 (es)
PT (1) PT2437753T (es)
RU (3) RU2732574C2 (es)
SI (1) SI2437753T1 (es)
SM (1) SMT201600437B (es)
TW (2) TWI494125B (es)
WO (1) WO2010141861A1 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Wave Life Sciences Japan リン原子修飾核酸の合成方法
HRP20161585T1 (hr) * 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
NZ602217A (en) 2010-03-11 2014-08-29 Immune Design Corp Vaccines for influenza
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
SG192759A1 (en) 2011-02-15 2013-09-30 Immune Design Corp Methods for enhancing immunogen specific immune responses by vectored vaccines
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
WO2013082500A2 (en) 2011-12-02 2013-06-06 Rhode Island Hospital Vaccine for falciparum malaria
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
SG10201610251PA (en) 2012-06-08 2017-01-27 Aduro Biotech Compositions and methods for cancer immunotherapy
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
PT2931738T (pt) 2012-12-13 2019-04-10 Aduro Biotech Inc Composições compreendendo nucleótidos cíclicos de purina com estereoquímica definida e métodos para a sua preparação e utilização
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
EP4398254A3 (en) 2013-04-29 2024-10-23 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3041478A4 (en) * 2013-09-05 2017-04-26 Immune Design Corp. Vaccine compositions for drug addiction
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10391167B2 (en) 2013-10-03 2019-08-27 Nitto Denko Corporation Mucosal vaccine composition
WO2015050181A1 (ja) 2013-10-03 2015-04-09 日東電工株式会社 注射ワクチン組成物
CA2923040A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Mucosal vaccine composition
CA2923026A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Nasal mucosal vaccine composition
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
EP3096764A1 (en) 2014-01-21 2016-11-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
EP3104878B1 (en) 2014-02-14 2019-05-22 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
JP6916113B2 (ja) 2015-11-27 2021-08-11 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
IL263030B2 (en) 2016-05-16 2024-11-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
KR102392974B1 (ko) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Tlr 작용제를 함유하는 제제 및 사용 방법
US20200148729A1 (en) 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3522893B1 (en) 2016-10-04 2024-12-04 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid a (asla) based therapeutics
KR102028463B1 (ko) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
AU2017389221B2 (en) 2016-12-26 2020-10-08 Access To Advanced Health Institute Herpes zoster vaccine composition
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3630076A1 (en) 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals SA Methods for manufacturing a liposome encapsulated rna
ES3003260T3 (en) 2017-06-15 2025-03-10 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and uses thereof
CN111315406A (zh) * 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
KR20200051778A (ko) 2017-09-13 2020-05-13 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
EP4410802A3 (en) 2018-02-12 2024-10-30 Inimmune Corporation Toll-like receptor ligands
US20190275135A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
US11446370B2 (en) 2019-03-18 2022-09-20 Janssen Pharmaceuticals, Inc. Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
SG11202110303XA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
US12533318B2 (en) 2019-08-30 2026-01-27 Glaxosmithkline Biologicals Sa Jet mixing lipid nanoparticle manufacturing process
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
AU2021208493B2 (en) 2020-01-16 2023-03-30 Janssen Pharmaceuticals, Inc. FimH mutant, compositions therewith and use thereof
BR112022019124A2 (pt) 2020-03-23 2023-02-14 Hdt Bio Corp Composições e métodos para liberação de rna
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022058945A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US12285483B2 (en) 2020-12-23 2025-04-29 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
EP4313135A1 (en) 2021-04-01 2024-02-07 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
EP4346896A4 (en) * 2021-05-27 2025-04-02 Revelation Biosciences, Inc. Mpla compositions and methods of use
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
EP4404917A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp RNA VACCINES AGAINST INFECTIOUS DISEASES
EP4404957A4 (en) 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
CA3232566A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Dried nanoparticle compositions
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
CN117105783A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 R-3-酰氧基-烷酸的合成方法、中间体及应用
CN117105888A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 一种mpla酰基链中间体的合成方法
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4844894A (en) 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4746742A (en) 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6544728B1 (en) 1986-01-22 2003-04-08 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US6054565A (en) 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (ja) 1986-07-01 1995-06-14 第一製薬株式会社 ジサツカライド誘導体含有鎮痛剤
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ES2160570T3 (es) 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
ATE159031T1 (de) 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US4981684A (en) 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2279020T3 (es) 1991-07-19 2007-08-16 The University Of Queensland Vacuna contra el papilomavirus humano.
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
CA2113720A1 (en) 1991-07-25 1993-02-04 Syamal Raychaudhuri Induction of cytotoxic t-lymphocyte responses
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
SG48390A1 (en) 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd E1a−f遺伝子
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
PT647140E (pt) 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
ATE494005T1 (de) 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichem papillomaviren hüllprotein und virus-ähnlichen teilchen
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DE69433728T2 (de) 1993-11-02 2004-09-30 Matsushita Electric Industrial Co., Ltd., Kadoma Halbleiterbauelement mit einem Aggregat von Mikro-Nadeln aus Halbleitermaterial
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
RU2154068C2 (ru) 1993-11-17 2000-08-10 Лаборатуар Ом С.А. Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (sv) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
DE59511047D1 (de) 1994-10-07 2006-06-14 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
JP3844501B2 (ja) 1995-02-08 2006-11-15 タカラバイオ株式会社 癌の制御
JP3958360B2 (ja) 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997011708A1 (en) 1995-09-29 1997-04-03 Eisai Research Institute Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
SE9600648D0 (sv) 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
CN1150001C (zh) 1996-07-03 2004-05-19 卫材株式会社 含有脂质a类似物的注射剂及其制备方法
DE69717664D1 (de) 1996-09-06 2003-01-16 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JPH10131046A (ja) 1996-10-29 1998-05-19 Nikka Chem Co Ltd 繊維の耐久性pH緩衝加工方法
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (de) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Leitungsanschlußschaltkreis
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
ES2248891T3 (es) 1997-02-25 2006-03-16 Corixa Corporation Compuestos para inmunodiagnostico de cancer de prostata y metodos para su uso.
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1998058956A2 (en) 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
US6764686B2 (en) 1997-07-21 2004-07-20 Baxter International Inc. Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CA2319309C (en) 1998-02-05 2010-08-10 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
CA2320041A1 (en) 1998-02-12 1999-08-19 American Cyanamid Company Vaccines comprising interleukin-12 and herpes simplex viral antigen
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
CA2324289C (en) 1998-03-09 2010-07-13 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
JP4227302B2 (ja) 1998-04-07 2009-02-18 コリクサ コーポレイション Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
NZ508013A (en) 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
AU766994B2 (en) 1998-08-25 2003-10-30 Ronald J. Gallenberg Beach cleaning apparatus and method
EP1111390A4 (en) 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd METHOD FOR EVALUATING INJECTIONS CONTAINING LIPID A ANALOGS
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2000095694A (ja) * 1998-09-24 2000-04-04 Sankyo Co Ltd 新規な医療用薬剤
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
WO2000062066A1 (en) 1999-04-07 2000-10-19 Hitachi Chemical Co., Ltd. METHOD FOR JUDGING AUTOIMMUNE DISEASE, METHOD FOR DETECTING ANTI-Reg PROTEIN AUTOANTIBODY AND DIAGNOSTICS FOR AUTOIMMUNE DISEASES
HK1044484B (en) 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
WO2001014544A1 (en) 1999-08-26 2001-03-01 Biovitrum Ab Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
ES2370262T3 (es) 1999-11-15 2011-12-14 Oncothyreon Inc. Análogos del lípido a sintéticos y sus utilizaciones.
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
AU2001269695B2 (en) 2000-05-19 2007-02-15 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
US7125549B2 (en) 2000-05-31 2006-10-24 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
ATE525078T1 (de) 2000-10-06 2011-10-15 Symbio Herborn Group Gmbh U Co Kyberdrug als autovakzine mit immunregulierenden wirkungen
ES2295229T3 (es) 2000-10-18 2008-04-16 Glaxosmithkline Biologicals S.A. Vacunas contra canceres.
WO2003004525A2 (en) 2001-01-26 2003-01-16 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
WO2002077195A2 (en) 2001-03-26 2002-10-03 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003021227A2 (en) 2001-09-05 2003-03-13 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
RU2288723C2 (ru) * 2002-02-04 2006-12-10 Корикса Корпорейшн Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
CN101138566B (zh) 2002-02-04 2012-05-23 科里克萨有限公司 用免疫效应化合物对感染性疾病和其它疾病的预防和治疗处理
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
AU2003228966C1 (en) 2002-05-09 2010-05-13 Oncothyreon Inc. Lipid A and other carbohydrate ligand analogs
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20050123550A1 (en) 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2862062B1 (fr) 2003-11-06 2005-12-23 Oreal Lipide a et composition topique, notamment cosmetique, le comprenant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
HRP20161585T1 (hr) * 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5328975B2 (ja) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 Rfパワーモジュール
EP3711768A1 (en) * 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis

Also Published As

Publication number Publication date
DK2437753T3 (en) 2016-12-19
AU2010256461A1 (en) 2012-01-12
CN105131051B (zh) 2020-07-10
EP2437753A4 (en) 2012-12-05
US9480740B2 (en) 2016-11-01
BRPI1011072B1 (pt) 2021-09-28
WO2010141861A1 (en) 2010-12-09
HUE031051T2 (en) 2017-06-28
SMT201600437B (it) 2017-01-10
MX393384B (es) 2025-03-24
IL216669A (en) 2016-04-21
JP5830015B2 (ja) 2015-12-09
US20180028649A1 (en) 2018-02-01
US10632191B2 (en) 2020-04-28
RU2015129468A3 (es) 2019-01-21
TW201544120A (zh) 2015-12-01
US20100310602A1 (en) 2010-12-09
TWI549688B (zh) 2016-09-21
SI2437753T1 (sl) 2016-12-30
CA2764374C (en) 2019-11-19
EP3124491A1 (en) 2017-02-01
CA2764374A1 (en) 2010-12-09
RU2560182C2 (ru) 2015-08-20
CN102481312A (zh) 2012-05-30
HRP20161585T1 (hr) 2016-12-30
PT2437753T (pt) 2016-11-23
US8722064B2 (en) 2014-05-13
ES2606563T3 (es) 2017-03-24
RU2015129468A (ru) 2015-12-27
TWI494125B (zh) 2015-08-01
US9814772B2 (en) 2017-11-14
IL216669A0 (en) 2012-02-29
US20140322268A1 (en) 2014-10-30
US20170182155A1 (en) 2017-06-29
JP2017137327A (ja) 2017-08-10
TW201102085A (en) 2011-01-16
RU2732574C2 (ru) 2020-09-21
RU2020129844A (ru) 2022-03-10
EP2437753B1 (en) 2016-08-31
JP2012528892A (ja) 2012-11-15
CN105131051A (zh) 2015-12-09
EP3124491B1 (en) 2019-10-30
PL2437753T3 (pl) 2017-03-31
CN102481312B (zh) 2015-07-15
JP2016028042A (ja) 2016-02-25
EP2437753A1 (en) 2012-04-11
MX360448B (es) 2018-11-01
LT2437753T (lt) 2016-12-12
BRPI1011072A2 (pt) 2016-04-12
AU2010256461B2 (en) 2016-03-17
IL242992B (en) 2018-01-31
CY1118347T1 (el) 2017-06-28
JP6251431B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
MX2011012836A (es) Adyuvantes sinteticos de glucopiranosil-lipido.
IN2012DN02736A (es)
WO2011027222A3 (en) Immunogenic compositions including tlr activity modulators
MX359517B (es) Composiciones, formulaciones y metodos de compuestos lipidicos modificadores de respuestas inmunitaria.
NO20091395L (no) Nye tiofenderivater
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
EP2056861A4 (en) IMPF-IMMUNOTHERAPY
ZA200904756B (en) Methods of vaccine administration
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
TW200942530A (en) Pyridine compounds
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
TW200732340A (en) Novel forms of tiotropium bromide and processes for preparation thereof
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
MX2009008767A (es) Utilizacion de lactobacillus casei para reforzar la proteccion inducida por la vacuna anti-gripal.
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
HK1224187A1 (zh) 针对药物成瘾的疫苗组合物

Legal Events

Date Code Title Description
FG Grant or registration